Join        Login             Stock Quote

UBS Securities Starts Intermune (ITMN) At 'Neutral', $13.50 PT

 April 12, 2012 10:56 PM

UBS Securities analyst Matthew Harrison initiated coverage of InterMune Inc. (NASDAQ:ITMN) with a "Neutral" rating and $13.50 price target.

Harrison likes InterMune's focus on orphan drugs as these markets generally yield high prices, data exclusivity and motivated patients. However, the continued uncertainty over EU pricing keeps him on the sidelines.

The analyst believes Esbriet, InterMune's product for Idiopathic Pulmonary Fibrosis (IPF), can be a $500 million drug even with an additional 15% price cut, but greater cuts would represent potential downside to his estimates.

Harrison models a blended pan-EU price which consists of an additional 15% price cut in Germany, a 20% price cut from the current German ex-factory price of 36,000 euros for France, Spain and Italy and a UK price equal to his assumed pan-EU price.

[Related -Analysts' Rating And Target Changes: AAPL, BA, DELL, ITMN, K, MOS, YELP]

While the analyst believes the recent German/France action puts somewhat of a floor on pricing, his EU reimbursement consultant believes negotiated pricing could be from 0-30% below current pricing. He does not model any US Esbriet sales. While he believes management has done the best it can to set up ASCEND for success, he still has concerns.

Based on January/February German IMS sales (about 10% sequential growth), BIBF 1120 enrollment and December IQWiG decision, the analyst sees limited Q1-2012 adds and expects a second half of 2012 rebound.

[Related -Strong Pre-Election Session]

While Harrison expects the stock to trade around quarterly revenue and be range-bound into year-end pricing clarity, he views the recent decline as an overshoot, and while he sees many positives in the ITMN story, current pricing uncertainty keeps him on the sidelines.

The brokerage introduced its 2012 loss per share estimate of $3.12, its 2013 loss estimate of $2.40 and its 2014 loss estimate of $0.73.

ITMN closed Thursday's regular trading up 0.97% at $11.99.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageDry Powder Doesn't Pay

Waiting for a correction to buy stocks is a fruitless read on...

article imageADP: US Private-Sector Jobs Rise 190k In August

Payrolls at US companies increased by a moderate 190,000 (seasonally adjusted) in August, according to this read on...

article imageThoughts on the Oil Bounce

Oil markets appeared to make too much of two small news items read on...

article imagePlan and Act, Don't React

An investor can and should learn from the past. He should never react to the recent past. Why? The past read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Mixed Day With Positive Technicals
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.